3D printing in pharmacy

2020 ◽  
pp. 58-60
Author(s):  
Yuliya Prozherina ◽  
Keyword(s):  
3D Printing ◽  
Cost Effective ◽  
Drug Market ◽  
Dosage Forms ◽  
Fixed Dose ◽  
Major Step ◽  
Combination Drugs ◽  
Effective Technology ◽  
Dose Combination ◽  
Research Stage

3D printing of drugs is an innovative and cost-effective technology, which is a major step towards personalized medicine. This technology can be used for the development of controlled-release drugs; fixed-dose combination drugs, as well as for the creation of orodispersible dosage forms. The global 3D drug market is still largely at the research stage, but its rapid growth is expected in the coming decade [1].

scholarly journals Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e049675
Author(s):  
Martine Hoogendoorn ◽  
Isaac Corro Ramos ◽  
Stéphane Soulard ◽  
Jennifer Cook ◽  
Erkki Soini ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
The Netherlands ◽  
Cost Effective ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Inhaled Corticosteroid ◽  
Dose Combination ◽  
Long Acting ◽  
Β2 Agonist ◽  
Country Specific

ObjectivesChronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator. This study assessed the cost-utility of the fixed dose combination of the bronchodilators tiotropium and olodaterol versus two comparators, tiotropium monotherapy and long-acting β2 agonist/inhaled corticosteroid (LABA/ICS) combinations, in three European countries: Finland, Sweden and the Netherlands.MethodsA previously published COPD patient-level discrete event simulation model was updated with most recent evidence to estimate lifetime quality-adjusted life years (QALYs) and costs for COPD patients receiving either tiotropium/olodaterol, tiotropium monotherapy or LABA/ICS. Treatment efficacy covered impact on trough forced expiratory volume in 1 s (FEV1), total and severe exacerbations and pneumonias. The unit costs of medication, maintenance treatment, exacerbations and pneumonias were obtained for each country. The country-specific analyses adhered to the Finnish, Swedish and Dutch pharmacoeconomic guidelines, respectively.ResultsTreatment with tiotropium/olodaterol gained QALYs ranging from 0.09 (Finland and Sweden) to 0.11 (the Netherlands) versus tiotropium and 0.23 (Finland and Sweden) to 0.28 (the Netherlands) versus LABA/ICS. The Finnish payer’s incremental cost-effectiveness ratio (ICER) of tiotropium/olodaterol was €11 000/QALY versus tiotropium and dominant versus LABA/ICS. The Swedish ICERs were €6200/QALY and dominant, respectively (societal perspective). The Dutch ICERs were €14 400 and €9200, respectively (societal perspective). The probability that tiotropium/olodaterol was cost-effective compared with tiotropium at the country-specific (unofficial) threshold values for the maximum willingness to pay for a QALY was 84% for Finland, 98% for Sweden and 99% for the Netherlands. Compared with LABA/ICS, this probability was 100% for all three countries.ConclusionsBased on the simulations, tiotropium/olodaterol is a cost-effective treatment option versus tiotropium or LABA/ICS in all three countries. In both Finland and Sweden, tiotropium/olodaterol is more effective and cost saving (ie, dominant) in comparison with LABA/ICS.

Availability and utilization of cardiovascular fixed-dose combination drugs in the United States

2015 ◽  
Vol 169 (3) ◽  
pp. 379-386.e1 ◽  
Author(s):  
Bo Wang ◽  
Niteesh K. Choudhry ◽  
Joshua J. Gagne ◽  
Joan Landon ◽  
Aaron S. Kesselheim
Keyword(s):  
United States ◽  
The United States ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Combination Drugs ◽  
Dose Combination

Fixed-dose combination drugs for the treatment of tuberculosis under India's RNTCP

2015 ◽  
Vol 19 (7) ◽  
pp. 870-871
Author(s):  
Karthik Laksham Balajee ◽  
S.A. Rizwan ◽  
Vaman Kulkarni ◽  
Vijay Silan
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Combination Drugs ◽  
Dose Combination

Safety and feasibility of outpatient TPX regimen.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e16057-e16057
Author(s):  
Dinesh Pendharkar ◽  
Hilal Ahmad
Keyword(s):  
Head And Neck ◽  
Cost Effective ◽  
Fixed Dose ◽  
Advanced Cancer Patients ◽  
Treatment Delays ◽  
Female Age ◽  
Dose Combination ◽  
Grade 3 ◽  
Loss Of Appetite ◽  
To Receive

e16057 Background: TPF has emerged as standard induction regimen in head and neck cancers. Along with docetaxel and platinum it involves continuous infusion of 5FU, which requires a prolonged admission or use of infusional devices, with added cost of treatment, not practical in many clinical situations and situations with limited resources. Keeping this in view, to make the schedule cost effective and outpatient based, we attempted to replace 5FU with oral capecitabine and study the safety and feasibility of TPX regimen (docetaxel, carboplatin and capecitabine) in advanced cancer patients. Methods: 12 patients (8 male, 4 female, age 51-67, median 58) with advanced metastatic disease, where palliative TPF regimen is generally used ,were prospectively planned to receive fixed dose combination of TPX regimen- docetaxel 120 mg day 1, carboplatin 450 mg day 2 and tab capecitabine 2000mg per day, in two divided doses, for five days q 3 weeks. There were 2 cases of cervical cancer, 3- GI tract and rest 7 had head and neck cancer. They were analysed for toxicity and tolerability. Results: In all 12 patients were given 39 courses of TPX regimen. The toxicities included weakness in 2/39 courses, loss of appetite 2/39, neutropenia grade 1 in 3/39, grade 2 in 3/39. During two course grade 3 neutropenia requiring intervention was recorded. The mucositis grade 1-2 was seen only on two occasions in previously radiated patients. There was no incidence of diarrhea. The treatment was well tolerated. All courses were given on time, and there were no treatment delays related to toxicity. Conclusions: TPX appears to be safe and feasible outpatient alternative to TPF. It has no infusional component allowing it to be used in day care setting. Efficacy data in bigger cohort is warranted.

Fixed-Dose Combination Drugs for Tuberculosis

Drugs ◽  
2003 ◽  
Vol 63 (6) ◽  
pp. 535-553 ◽  
Author(s):  
Bj??rn Blomberg ◽  
Bernard Fourie
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Combination Drugs ◽  
Dose Combination

Use of Fixed-Dose Combination Drugs for the Treatment of Glaucoma

Drugs & Aging ◽  
2007 ◽  
Vol 24 (12) ◽  
pp. 1007-1016 ◽  
Author(s):  
Albert S Khouri ◽  
Tony Realini ◽  
Robert D Fechtner
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Combination Drugs ◽  
Dose Combination
Sign in / Sign up

Export Citation Format

Share Document